➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Medtronic
Baxter
Moodys
Mallinckrodt
McKinsey
McKesson

Last Updated: September 20, 2021

DrugPatentWatch Database Preview

Claims for Patent: 10,087,260

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

Summary for Patent: 10,087,260
Title:Anti-HER2 antibody and conjugate thereof
Abstract: Disclosed are an anti-HER2 antibody and conjugate of the anti-HER2 antibody and small molecule medicine. Also disclosed are uses of the antibody and conjugate thereof in preparing medicine for treating tumor.
Inventor(s): Fang; Jianmin (Yantai, CN), Huang; Changjiang (Yantai, CN), Jiang; Jing (Yantai, CN), Yao; Xuejing (Yantai, CN), Li; Hongwen (Yantai, CN), Xu; Qiaoyu (Yantai, CN), Li; Zhuanglin (Yantai, CN)
Assignee: REMEGEN, LTD. (Yantai, CN)
Application Number:15/037,104
Patent Claims:1. An antibody or functional fragments thereof which can specifically bind to HER2, wherein the antibody comprises a heavy chain and a light chain, in which: (i) the heavy chain comprises three CDR regions, wherein the CDR regions have the amino acid sequence as shown in SEQ ID NO: 1, 2 and 3, respectively; and (ii) the light chain comprises three CDR regions, wherein the CDR regions have the amino acid sequence as shown in SEQ ID NO: 4, 5 and 6, respectively.

2. The antibody or functional fragments thereof according to claim 1, wherein the antibody is an antibody secreted from the hybridoma cells which were deposited at the China General Microbiological Culture Collection Center on Aug. 22, 2013, with the deposit number of CGMCC No. 8102.

3. The antibody or functional fragments thereof according to claim 1, wherein the antibody is a humanized antibody.

4. The antibody or functional fragments thereof according to claim 1, wherein the antibody is secreted from the CHO cells which were deposited at the China Center for Type Culture Collection on Nov. 6, 2013, with the deposit number of CCTCC C2013170.

5. An isolated polynucleotide, which encodes the antibody or functional fragments thereof according to claim 1.

6. A combination of the isolated polynucleotides, which comprises: a polynucleotide encoding the light chain of the antibody or functional fragments thereof according to claim 1 and a polynucleotide encoding the heavy chain of the antibody or functional fragments thereof according to claim 1.

7. A conjugate, which comprises the antibody or functional fragments thereof according to claim 1 which are conjugated with one or more therapeutic agents.

8. The conjugate according to claim 7, wherein the therapeutic agent is coupled with the antibody or the functional fragments thereof through a linker Previously presented.

9. The conjugate according to claim 7, wherein the conjugate has the general formula of Ab-(L-U)n, in which Ab represents the antibody or functional fragments thereof according to claim 1, L represents a linker, U represents a therapeutic agent, and n represents an integer from 1 to 8.

10. A pharmaceutical composition, which comprises the antibody or functional fragments thereof according to claim 1 and/or the conjugate according to claim 7, as well as a pharmaceutically acceptable carrier.

11. The conjugate according to claim 7, wherein the therapeutic agent is selected from cytotoxic drug, immunopotentiators and radioactive isotopes.

12. The conjugate according to claim 7, wherein the therapeutic agent is selected from dolastatin and derivatives thereof.

13. The conjugate according to claim 7, wherein the therapeutic agent is selected from MMAE and MMAF.

14. The conjugate according to claim 8, wherein the linker is linked with the antibody through thiol.

15. The conjugate according to claim 8, wherein the linker is selected from mc-vc-pAB or mc.

16. A method for treating cancer, comprising administering the pharmaceutical composition according to claim 10 in a therapeutically effective amount to a subject in need thereof.

17. The method according to claim 16, wherein the cancer is HER2-positive cancer.

18. The method according to claim 17, wherein the cancer is breast cancer, ovary cancer or gastric cancer.

19. The method according to claim 17, wherein the cancer is Lapatinib- and/or trastuzumab-resistant breast cancer, ovary cancer or gastric cancer.

Summary for Patent: ⤷  Free Forever Trial

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
China2013 1 0586326Nov 19, 2013
PCT Information
PCT FiledNovember 18, 2014PCT Application Number:PCT/CN2014/091332
PCT Publication Date:May 28, 2015PCT Publication Number:WO2015/074528

Details for Patent 10,087,260

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech HERCEPTIN trastuzumab VIAL; INTRAVENOUS 103792 001 1998-09-25 ⤷  Free Forever Trial REMEGEN, LTD. (Yantai, CN) 2033-11-19 RX Orphan search
Genentech Inc HERCEPTIN HYLECTA trastuzumab; hyaluronidase-oysk INJECTABLE;SUBCUTANEOUS 761106 001 2019-02-28 ⤷  Free Forever Trial REMEGEN, LTD. (Yantai, CN) 2033-11-19 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Mallinckrodt
Dow
McKesson
AstraZeneca
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.